NCT06461910 2026-03-03
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
Clinical Trials
33 trialsNCT05451290 2026-02-12
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT07165847 2025-09-10
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT07007182 2025-09-05
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT06988956 2025-05-25
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03406299 2025-05-22
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT05223088 2025-03-18
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Completed
NCT06354140 2024-07-17
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT06439550 2024-06-03
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT06339619 2024-04-01
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06187597 2024-03-12
EC-CRT-007
Sun Yat-sen University
Phase 2 Recruiting
NCT00004860 2023-06-15
Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05594381 2022-10-26
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05070598 2021-10-07
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
Shengjing Hospital
Phase 2 Unknown
NCT03415802 2021-02-01
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
ChineseAMS
Phase 2 Completed
NCT03154983 2020-12-09
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Zhongnan Hospital
Phase 2 Unknown
NCT04571489 2020-10-01
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
Lee's Pharmaceutical Limited
Phase 2 Unknown
NCT04216758 2020-06-30
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer
Fudan University
Phase 2 Unknown
NCT04202484 2019-12-17
Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma
RenJi Hospital
Phase 2 Unknown
NCT02527785 2017-08-23
Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer
Hallym University Medical Center
Phase 2 Completed
NCT03204032 2017-06-29
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
ChineseAMS
Phase 2 Unknown
NCT02447679 2017-02-07
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
Chang Gung Memorial Hospital
Phase 2 Completed
NCT01050426 2016-10-14
PERU
Royal Marsden NHS Foundation Trust
Phase 2 Terminated
NCT02903498 2016-10-12
The Maintenance Treatment of UFT in Advanced Gastric Cancer
Fudan University
Phase 2 Completed
NCT02623153 2015-12-07
Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT02280070 2014-10-31
RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).
Clinical Research Support Center Kyush
Phase 2 Unknown
NCT01225744 2014-06-11
eSCOUT
The Christie NHS Foundation Trust
Phase 2 Completed
NCT02090153 2014-03-18
Study of S-1 Plus LV for Advanced Gastric Cancer
Sun Yat-sen University
Phase 2 Completed
NCT00519688 2011-10-17
UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 2 Completed
NCT00464919 2009-07-07
Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)
National Taiwan University Hospital
Phase 2 Completed
NCT00890188 2009-05-07
UFUR
National Cheng-Kung University Hospital
Phase 2 Unknown
NCT00384800 2009-02-09
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Far Eastern Memorial Hospital
Phase 2 Unknown
NCT00037089 2005-06-24
A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer
Edelman, Martin, M.D.
Phase 2 Unknown